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Abstract
Background:  Significant evidence suggests that a promoter polymorphism withinthe gene
SLC11A1 is involved in susceptibility to both autoimmune and infectious disorders. The aim of this
study was to evaluate whether SLC11A1 has a role in the susceptibility to inflammatory bowel
disease (IBD) by characterizing a promoter polymorphism within the gene and two short tandem
repeat (STR) markers in genetic proximity to SLC11A1.
Methods: The studied population consisted of 484 Caucasians with IBD, 144 population controls,
and 348 non-IBD-affected first-degree relatives of IBD patients. IBD subjects were re-categorized
at the sub-disease phenotypic level to characterize possible SLC11A1  genotype-phenotype
correlations. Polymorphic markers were amplified from germline DNA and typed using gel
electrophoresis. Genotype-phenotype correlations were defined using case-control, haplotype,
and family-based association studies.
Results: This study did not provide compelling evidence for SLC11A1 disease association; most
significantly, there was no apparent evidence of SLC11A1 promoter allele association in the studied
Crohn's disease population.
Conclusion: Our results therefore refute previous studies that have shown SLC11A1 promoter
polymorphisms are involved in susceptibility to this form of IBD.
Background
Inflammatory bowel disease (IBD) encompasses a
number of disorders that are characterized by chronic
inflammation of the gastrointestinal tract. The three spe-
cific forms of the disease known as Crohn disease (CD),
ulcerative colitis (UC), or the less well-characterized inde-
terminate colitis (IC), are diagnosed based on the results
of clinical observations, histology, radiology, and to a
lesser extent, serology. Prominent clinical features include
profuse diarrhea, abdominal pain, and increased colorec-
tal cancer risk. IBD affects an estimated one million Amer-
icans [1], with UC being the more prevalent form. Current
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pathogenic models state that IBD develops in a genetically
susceptible individual in response to environmental stim-
uli [2].
The aim of this study was to investigate the role of the
gene SLC11A1 in the susceptibility to IBD. SLC11A1 is a
proton-coupled bivalent metal antiporter that is crucial in
early macrophage activation [3]. SLC11A1  encodes a
highly hydrophobic 550 amino acid membrane protein
and is located on the long arm of chromosome 2 (2q35),
a region that has not been identified as being within an
IBD susceptibility locus. Genetic studies have shown that
different alleles of a (GT)n dinucleotide repeat polymor-
phism located within the promoter region of SLC11A1
cause susceptibility to different human diseases. Allele 2
of this polymorphism is associated with susceptibility to
intracellular pathogen infection [4], and allele 3 is associ-
ated with autoimmune disease susceptibility [3].
SLC11A1 has been implicated in susceptibility to IBD.
Previous work from this laboratory [5] has shown that
two tetranucleotide short tandem repeat (STR) polymor-
phisms genetically linked to SLC11A1 are associated with
CD [5]. The (GT)n promoter polymorphism, however,
was not examined in that study. A recent study by Kojima
et al [6] indicated that promoter polymorphism allele 7
was associated with IBD in a Japanese population.
In our current work, we used a case-control association
study to define the role of the (GT)n promoter polymor-
phism in susceptibility to IBD and to further characterize
the STR markers previously described [5]. These markers
(D2S434 and D2S1323) are 0.67 Mbp proximal and 3.44
Mbp distal of SLC11A1, respectively.
Methods
Population
This prospective study was approved by the University of
Louisville Institutional Review Board. Written informed
consent was obtained from all subjects. Patients were
derived from a University-based colon and rectal surgery
practice. Initial IBD diagnoses were determined through
radiological, endoscopic, and/or histopathological stud-
ies. Histology was available in all cases.
The study population consisted of a total of 628 Cauca-
sians, including 254 unrelated individuals with CD (63%
women), 165 with UC (53% women), 65 with IC (70%
women), and 144 population controls (74% women).
Demographic data for the IBD population is shown in
Table 1. For the purposes of more accurate phenotyping,
the CD group was subdivided based on the Vienna classi-
fication [7]. This categorizes CD patients based on age of
onset (A), location of disease (L), and disease behavior
(B). With regard to age of onset, 175 of 254 (69%) CD
patients were diagnosed at < 40 years of age (A1 group)
and 47 of 254 (18%) had disease diagnosed at ≥ 40 years
of age (A2 group). Information regarding age of onset was
not available for 32 of 254 patients (13%). Regarding dis-
ease location, 70 of 254 (28%) had terminal ileal disease
(L1 group), 152 of 254 (60%) had purely colonic and/or
ileocolic (ileal and colonic) disease (L2/L3 groups), and
32 of 254 (13%) had disease located proximal to terminal
ileum (L4 group). The L2 and L3 groups were combined
for the purposes of this study, since colonic disease consti-
tutes the primary focus of our group. Regarding disease
behavior, 96 of 254 (38%) had uncomplicated inflamma-
tory disease (B1 group), 28 of 254 (11%) had stricturing
disease (B2 group), and 130 of 254 (51%) had penetrat-
ing disease (B3 group).
A total of 348 non-affected first-degree relatives of IBD
patients were available for the study. There were 63 CD
families (29 triads, 30 discordant sibling pairs, 4 triad/dis-
cordant sibling pair combinations), 43 UC families (11
triads, 24 discordant sibling pairs, 8 triad/discordant sib-
ling pair combinations), and 14 IC families (5 triads, 5
discordant sibling pairs, 4 triad/discordant sibling pair
combinations). In addition, there were 17 CD families, 18
Table 1: General characteristics of the studied inflammatory bowel disease (IBD) population.
Disease characteristic Crohn's disease (n = 254) Ulcerative Colitis (n = 165) Indeterminate colitis (n = 65)
Average length of clinical follow-up 
(range, yrs)
4.6 (0–16) 4.3 (0–14) 5.6 (0–12)
Age of IBD onset (range, yrs) 29.2 (6–81) 34.4 (10–75) 29.7 (12–64)
Surgical treatment for IBD 
complications (% received)
75% 67% 82%
First-degree relative with IBD 36% 20% 22%
Extraintestinal manifestations(a) 43% 36% 49%
(a) Extraintestinal manifestations are defined as IBD-related disease outside the gastrointestinal tract involving joints, eyes, hepatobiliary system, or 
the skin.BMC Medical Genetics 2005, 6:10 http://www.biomedcentral.com/1471-2350/6/10
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UC families, and 9 IC families who could not be classified
as either a triad or discordant sibling pairs.
Markers and genotyping
STRs were amplified from genomic DNA extracted from
peripheral leukocytes. Polymerase chain reaction (PCR)
primers were custom-synthesized (Proligo, La Jolla, CA).
PCR amplification of the SLC11A1  promoter polymor-
phism was performed using 100 ng template DNA, 2.5
mM MgCl2, 50 mM KCl, 10 mM of tris/HCl, 0.2 µM of
each dNTP, 200 pmol of each primer, and 1 unit of Taq
polymerase (Promega, Madison, WI). Primer sequences
were as follows: 5'GACATGAAGACTCGCATTAG3' &
5'TCAAGTCTCCACCAGCCTAGT3'. The product was
amplified using the following conditions: 94°C for 10
min, followed by 25 cycles of 94°C for 30 sec, 55°C for
75 sec, and 72°C for 20 sec. A final extension step was run
at 72°C for 6 min. Genotyping was performed using gel
electrophoresis (Spreadex EL 300 S-100 gel [Elchrom Sci-
entific, Lake Park, FL]). PCR amplification of the STR
markers D2S434 and D2S1323 was performed as
described previously [5].
Statistical analyses
Case-control tests of association
Case-control analyses were performed using STR geno-
type-allele frequencies in cohorts subdivided on the vari-
ables outlined in Table 1. Correction for multiple testing
was performed by using Storey's q-value method, where
p-values were adjusted according to the experimental false
discovery rate (FDR) [8]. The global null hypothesis of no
difference in genotype-allele frequency between controls
and any of the other groups was tested by using Fisher's
method [9], which was used to combine all of the control
group comparison global p-values obtained for each of
the three markers. Q-values were calculated from these
global p-values using the QVALUE program [10] with the
tuning parameter λ  = 0, which dictates the assumption π o
= 1, where π o is the proportion of tests in which the null
hypothesis is true.
To limit the number of individual disease-control geno-
type-allele comparisons, further analyses were only per-
formed in those disease groups possessing a global test q-
value <0.05. Therefore, 2 × 2 contingency tables were only
constructed for genotypes with a global test q-value meet-
ing this condition. Disease versus  control comparisons
were performed using Fisher's exact test and corrected for
multiple testing using the q-value method as described
above.
Since IBD affecting the colon is the primary focus of our
research, the L2 colonic CD and L3 ileocolonic CD groups
were combined, enabling maximization of statistical
power. We argue that this approach will not impair the
validity of statistical analyses given that the Vienna Classi-
fication is somewhat arbitrary and that group genetic
homogeneity may be increased by combining all those
cases with colonic IBD. Furthermore, owing to the rela-
tively low numbers of individuals with CD proximal to
the terminal ileum (L4 group, n = 32), this disease sub-
group was excluded from case-control analyses.
Family-based tests of association
Family-based tests used included the pedigree disequilib-
rium test (PDT) [11,12] and a likelihood ratio test imple-
mented in the computer program TRANSMIT [13]. PDT
analysis has distinct advantages over other family-based
tests of association. PDT allows for analysis of data from
related nuclear families and discordant sibling pairs from
extended pedigrees. The likelihood ratio test, as imple-
mented in the computer program TRANSMIT [13], can
account for missing parental genetic data by inferring
parental genotypes based on the genotypes of their off-
spring. To maximize power, family-based analyses were
not performed at the sub-phenotypic level.
Results
Allele and genotype frequencies
Alleles for the SLC11A1  promoter polymorphism STR
D2S434 and STR D2S1323 were named numerically
according to molecular weight, with "1" representing a
larger allele than "2" and so on. Allele distributions are
shown in Table 2.
DNA sequence analysis of the three SLC11A1 promoter
polymorphism alleles identified in the study population
revealed the following sequences:
Allele 1: T(GT)5AC(GT)5AC(GT)11GGCAGA(G)6
Allele 2: T(GT)5AC(GT)5AC(GT)10GGCAGA(G)6
Allele 3: T(GT)5AC(GT)5AC(GT)9GGCAGA(G)6
These sequences corresponded to alleles 1, 2, and 3 as
described by Searle and Blackwell [14]. Alleles 4–7 were
not identified in this population.
Case-control association studies
Results from global disease versus control comparisons of
the studied markers are shown in Table 3. Analysis of gen-
otype and allele frequencies for the (GT)n promoter poly-
morphism did not reveal any evidence of association.
Additionally, we studied STR markers in genetic proximity
to  SLC11A1. The STR D2S1323 exhibited evidence of
association with the test of the global null hypothesis of
homogeneity of all groups exhibiting statistical signifi-
cance for allele frequencies (q = 0.050, p = 0.008). To limit
multiple testing, individual pair-wise disease versus con-BMC Medical Genetics 2005, 6:10 http://www.biomedcentral.com/1471-2350/6/10
Page 4 of 6
(page number not for citation purposes)
trol comparisons were only performed for D2S1323 alle-
les. These analyses showed over-representation of allele 1
in the UC group (q = 0.022, p = 0.005; UC frequency 78
of 100 alleles [78%] versus control frequency 54 of 92 alle-
les [59%]). The STR D2S434 did not reveal any evidence
of association. Further analyses of genotype and allele
data for all markers did not show a correlation with either
age of onset or disease behavior.
Family-based association studies
Family-based tests were performed for each of the three
markers. Neither the likelihood ratio test nor the PDT
Table 2: Polymorphism allele frequencies.
SLC11A1 
Promoter Allele
Ulcerative Colitis Indeterminate Colitis Ileocolic Crohn's 
Disease (L1)
Colonic Crohn's 
Disease (L2/3)
Controls
N%N%N%N % N %
1 0000000 0 2 1
2 4 02 11 92 12 82 94 4 2 5 4 2 2 3
3 152 79 71 79 68 71 132 75 136 76
Total 192 90 96 176 180
D2S434 Allele N % N % N % N % N %
3 2 33 02 22 42 22 54 8 1 2 2 5 1 4
4 5 32 92 32 62 32 64 6 2 7 5 2 3 0
5 4 33 02 32 72 42 64 8 2 2 4 7 2 7
6 2 31 91 79 8 1 93 0 1 2 3 0 1 7
Pooled(a) 16 14 5 12 11 6 22 8 20 11
Total 158 90 88 194 174
D2S1323 Allele N % N % N % N % N %
1 7 87 82 87 03 97 28 3 6 7 5 4 5 9
2 2 22 21 23 01 52 84 1 3 3 3 8 4 1
Total 100 40 54 124 92
(a) Pooled alleles with frequency <5%
Table 3: Case-control association global q-value and p-values for disease group versus control comparisons.
STR marker Disease versus control comparison global p-value Global test of homogeneity(a)
Ulcerative 
colitis
Indeterminate 
colitis
Terminal ileal 
Crohn's disease (L1)
Colonic Crohn's 
disease (L2/3)
Combined p-value q-value
Promoter (GT)n Genotype 0.553 0.424 0.743 0.768 0.855 0.855
Allele 0.457 0.548 0.473 1.000 0.832 0.855
D2S434 Genotype 0.390 0.345 0.365 0.705 0.562 0.842
Allele 0.930 0.191 0.157 0.153 0.206 0.412
D2S1323 Genotype 0.027 0.424 0.202 0.490 0.093 0.279
Allele 0.005 0.247 0.111 0.253 0.008 0.050
(a) Statistically significant comparisons following correction for multiple testing are shown in bold typefaceBMC Medical Genetics 2005, 6:10 http://www.biomedcentral.com/1471-2350/6/10
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revealed significant evidence of association for any of
these markers.
Discussion
No association was observed between any SLC11A1 pro-
moter polymorphism alleles and any IBD sub-phenotypic
group in this population, which unexpectedly refutes the
significant evidence of others [6]. This result was some-
what surprising, given that many studies have shown
SLC11A1 promoter polymorphisms to be involved in sus-
ceptibility to autoimmune disorders and disorders that
are characterized by a high degree of immunological dys-
regulation, including IBD [3]. Searle and Blackwell [14]
investigated the enhancer properties of each of the four
identified promoter polymorphism alleles. Allele 3 was
found to have endogenous enhancer activity, whereas
alleles 1, 2, and 4 were poor promoters in the absence of
exogenous stimuli. Stimulation of macrophages with bac-
terial lipopolysaccharide (LPS) had minimal effects on
SLC11A1 expression driven by alleles 1, 2, and 4; how-
ever, allele 3-driven SLC11A1 expression was enhanced. It
has long been recognized that altered expression of
SLC11A1 in response to LPS is a key event in the activation
of macrophages upon contact with a variety of pathogens
[15].
Based on those observations, we hypothesized that over-
representation of promoter allele 3 in CD patients could
lead to hyperactivation of bowel wall macrophages that
are chronically exposed to high levels of LPS. This could
subsequently cause the autoimmune-like phenotype char-
acteristic of IBD. This hypothesis must be rejected in this
cohort due to the absence of association with promoter
allele 3 in any IBD subgroup. Analysis of intragenic single
nucleotide polymorphisms are required to conclusively
exclude SLC11A1 as an IBD candidate gene.
D2S1323 was associated with UC in this population.
Indeed, this was the only evidence for association in any
of the studied STR markers in proximity to SLC11A1. This
association was not, however, confirmed upon family-
based statistical analysis. The current finding was particu-
larly surprising to us, given that our previous study
showed this STR to be associated with CD rather than UC
[5]. The significance of this finding is thus uncertain, and
the divergent outcomes from the current and earlier stud-
ies could be considered somewhat concerning. We do,
however, believe that a number of prominent features of
the current study render our results of higher validity than
those of our previous study. An important feature of our
current work is that all histological specimens from our
subjects have been reviewed by a single gastrointestinal
pathologist. This was not the case in the earlier study, and
diagnostic misclassification (i.e., UC and/or IC incorrectly
diagnosed as CD and vice versa) may have been a con-
founding variable that may have in part led to what we
now consider the false-positive association observed in
the CD population. It should also be noted that the cur-
rent study contains over two-fold the number of subjects
as compared with the previous work, and thus statistical
power has been significantly increased. Furthermore, our
current statistical methodology is now far superior, and
we argue that our stringent means of correcting for the
effects of multiple testing effectively minimizes the likeli-
hood of detecting a false-positive association. This is a vast
improvement over our earlier study in which compound-
ing of a type 1 error was not taken into account. Finally,
genotyping in the earlier study was performed on speci-
mens with a rather heterogeneous nature and consisted of
genetic data derived from DNA extracted from both surgi-
cal specimens (i.e., somatic DNA) and leukocytes (i.e.,
germline DNA). In our current study, genetic material has
only been isolated from leukocytes, thus reducing the pos-
sibility of detecting variations within somatic DNA.
Conclusion
In summary, we have characterized the SLC11A1 (GT)n
promoter polymorphism in IBD sub-phenotypic groups
and accept the null hypothesis as confirmed by family-
based testing. We did, however, identify an association
between an allele of the STR D2S1323 and UC upon case-
control analysis. This association was not confirmed on
family-based and haplotype testing, and its actual signifi-
cance in IBD remains to be seen.
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